Holen Sie sich die Stockscreener-App
25.86
0.78%
0.20
Handel nachbörslich:
25.86
Schlusskurs vom Vortag:
$25.66
Offen:
$25.44
24-Stunden-Volumen:
2.76M
Relative Volume:
3.29
Marktkapitalisierung:
$3.80B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-323.01M
KGV:
-13.40
EPS:
-1.93
Netto-Cashflow:
$-272.30M
1W Leistung:
-1.60%
1M Leistung:
-1.18%
6M Leistung:
-5.24%
1J Leistung:
-28.52%
1-Tages-Spanne:
$25.25
$26.27
1-Wochen-Bereich:
$25.25
$28.08
52-Wochen-Spanne:
$24.61
$45.58
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
25.86 | 3.80B | 0 | -323.01M | -272.30M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Wells Fargo & Company Issues Pessimistic Forecast for Immunovant (NASDAQ:IMVT) Stock Price - Defense World
Wells Fargo & Company Lowers Immunovant (NASDAQ:IMVT) Price Target to $45.00 - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.89 Consensus Target Price from Analysts - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Down 5.2%Should You Sell? - MarketBeat
Immunovant's SWOT analysis: biotech stock poised for growth in Graves' disease - Investing.com India
State Street Corp Buys 303,386 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Head to Head Contrast: Jasper Therapeutics (NASDAQ:JSPR) versus Immunovant (NASDAQ:IMVT) - Defense World
The Manufacturers Life Insurance Company Has $1.05 Million Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Charles Schwab Investment Management Inc. Has $15.75 Million Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Redmile Group LLC Decreases Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant's SWOT analysis: stock undervalued amid promising Graves' disease treatment - Investing.com UK
Immunovant director Atul Pande sells shares for $221,185 By Investing.com - Investing.com Canada
Immunovant director Atul Pande sells shares for $221,185 - Investing.com
(IMVT) Investment Analysis and Advice - Stock Traders Daily
Bamco Inc. NY Sells 25,000 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Erste Asset Management GmbH Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Baker BROS. Advisors LP Raises Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Fmr LLC Increases Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Intech Investment Management LLC Buys Shares of 21,825 Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Algert Global LLC Sells 83,969 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Contrasting Immunovant (NASDAQ:IMVT) and enGene (NASDAQ:ENGN) - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Receives $48.10 Average Target Price from Analysts - Defense World
Have Immunovant Insiders Been Selling Stock? - Simply Wall St
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Buy" by Brokerages - MarketBeat
KBC Group NV Purchases 612 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 56,789 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Trend Tracker for (IMVT) - Stock Traders Daily
Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $106,228.30 in Stock - MarketBeat
Insider Selling: Immunovant, Inc. (NASDAQ:IMVT) CEO Sells 16,692 Shares of Stock - MarketBeat
Immunovant CEO Peter Salzmann sells shares for $424,811 By Investing.com - Investing.com South Africa
Immunovant CFO Eva Renee Barnett sells $106,228 in stock By Investing.com - Investing.com South Africa
Immunovant CEO Peter Salzmann sells shares for $424,811 - Investing.com
Immunovant CFO Eva Renee Barnett sells $106,228 in stock - Investing.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Victory Capital Management Inc. - Defense World
Victory Capital Management Inc. Has $9.56 Million Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - MSN
Immunovant stock hits 52-week low at $24.66 amid market shifts - Investing.com Nigeria
Principal Financial Group Inc. Purchases 391,436 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Technical Data - Stock Traders Daily
FMR LLC's Strategic Acquisition of Immunovant Inc Shares - GuruFocus.com
Immunovant: Pipeline Progressing With One Minor Delay (NASDAQ:IMVT) - Seeking Alpha
Immunovant (NASDAQ:IMVT) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat
Analysts Provide An Important Insights On Immunovant Inc (IMVT) - Stocks Register
Immunovant’s Strategic Advances in Autoimmune Therapies - TipRanks
Interesting IMVT Put And Call Options For March 2025 - Nasdaq
Immunovant's (IMVT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunovant Inc-Aktie (IMVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hughes Douglas J. | Director |
Dec 02 '24 |
Sale |
28.54 |
5,425 |
154,830 |
119,585 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):